Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used for type 2 diabetes and obesity29, demonstrated a consistent and robust protective effect across both cohorts (Fig. 3c). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.